The Cannigma

JUNE 30, 2021

On July 1st, 2021, new cannabis legalization are going into effect in Connecticut, New Mexico, and Virginia, just a couple days after a recreational cannabis legalization measure went into effect in South Dakota. As of July 1, 2021, all five states had both adult-use and medical cannabis programs. ? Spasms 4,937 21.9% PTSD 3,440 15.2%

Chronic Pain 137

Chronic Pain Marijuana Conditions Patients 137

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

TheAnswerPage

NOVEMBER 19, 2021

According to a study published in the October 2021 edition of Cancer, what is the most common time for breast cancer patients to use cannabinoid-based products: pre-treatment, during treatment or after treatment? 24% used the cannabinoids pre-treatment, 79% during treatment and 54% after treatment.

Treatment 52

Treatment Cannabinoids Data Patients 52

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. The analogy would be this. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

SpeedWeed

FEBRUARY 21, 2021

February 18, 2021. | If successful, data from (Kaminski’s) pre-clinical study would be used as part of the support for an Independent New Drug filing with the FDA,” said Small-Howard. The post Cannabis mixtures studied as treatment for COVID inflammation appeared first on SpeedWeed. Published.

Treatment 52

Treatment Research and Development Cannabinoids Data 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE:

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. Queensland was the source of 51% of prescriptions between 2016 and 2021.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. We expect to report this data as it becomes available and after submission to the FDA. During the six months ended September 30, 2021, the Company raised approximately $4.1

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JUNE 1, 2021

TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – RYAH Group, Inc. The 5-year study is expected to cover tens of thousands of patients suffering from chronic pain, which makes it one of the largest and most ambitious research projects to be conducted in the plant-based treatment arena. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 4, 2021

The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021. The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

SEPTEMBER 23, 2021

This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction. Toronto, Ontario, Sep 23, 2021 (Newsfile Corp via COMTEX) — Toronto, Ontario–(Newsfile Corp. – September 23, 2021) – Awakn Life Sciences Corp., (NEO: Treatment of AUD rates are low at 16%.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. The Marijuana Regulatory Agency issued a request for proposals for the 2021 Veteran Marijuana Research Grant Program on Tuesday, June 1. Between Dec.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Veriheal

AUGUST 31, 2022

Nonetheless, the data speaks differently. . The research letter written by Dr. Harocopos and his team looked into the first two months of OPC operation by collecting data from program staff on individuals using the services at the two OPC sites. 30, 2021, and Jan. The Research Letter. 31, 2022, 78% identified as male, 36.9%

Consumption 104

Consumption Data Treatment Collective 104

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. 3 Nature Aging | VOL 1 | July 2021 | p. Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JUNE 23, 2021

TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — RYAH Group, Inc. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

MARCH 17, 2022

COVID-related border restrictions did not cause immediate major interruption to Australia’s drug markets, but wastewater data strongly indicates that the cumulative effect of these restrictions led to some substantial market interruptions. The latest report presents data on Australia’s drug consumption for 12 substances.

Consumption 52

Consumption Programs Data Treatment 52

Cannabis Law Report

APRIL 13, 2022

(The Center Square) – Marijuana sales in Colorado continued a downward trend in February totaling $145 million, according to the state’s latest market data. February marked the third consecutive month of declining marijuana sales following a record-breaking year in 2021, the Colorado Department of Revenue’s (CDOR) figures show.

Marijuana 52

Marijuana Data Retail Collective 52

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. 1, 2020, and July 31, 2021—a 43% increase from the same period a year before. These statistics place four Texas cities in the top 25 for opioid misuse in the nation.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Canna Law Blog

DECEMBER 16, 2021

On Monday, November 13, 2021, New York Assemblyman Pat Burke introduced medical psilocybin legislation. Qualifying medical practitioners would need to take a two-hour training course provided by the Department of Health in order to certify patients for psilocybin treatment. Rules and Restrictions.

Legislation 96

Legislation Treatment Therapy Conditions 96

Cannabis Law Report

SEPTEMBER 15, 2021

More than 100 people in the US have been hospitalized in 2021 after using Delta-8 THC products, federal health regulators warned Tuesday. National poison control centers received 661 exposure cases of delta-8 THC products between January 2018 and July 31, 2021, 660 of which occurred between January 1, 2021, and July 31, 2021.

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

AUGUST 2, 2021

CHICAGO , July 15, 2021 /PRNewswire/ — P alo Santo , the leading U.S.-based In 2020, founders Daniel Goldberg , Tim Schlidt and Tony Eisenberg partnered to form Palo Santo, and formally launched the venture capital fund in 2021. Here’s the press release. Tweet this.

Research and Development 98

Research and Development Therapy Collective Treatment 98

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

JULY 19, 2021

July 19, 2021 07:58 ET | Source: Potbotics, Inc. Toronto, July 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — RYAH Group, Inc. This is a precedent-setting experiment that is expected to generate the data needed to facilitate an accurate milligram dosing experience with dry herb.”. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

DECEMBER 11, 2021

This reduction in prices will make the clinic the cheapest option for many patients looking to receive medical cannabis treatments for a wide variety of conditions and illnesses. Medical cannabis can be considered as a treatment for a number of conditions – including chronic pain, epilepsy, and insomnia – when first-line options have failed.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. Patients who met eligibility criteria were able to continue ganaxolone treatment during a 24-week extension to the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

SpeedWeed

SEPTEMBER 18, 2021

Charlotte’s Web took the unusual step of issuing a public response to the refusals, available here , with a link to the company’s also public letter to the FDA here , which responds directly to the agency’s criticisms of the data provided and alleging factual inaccuracies in its response. Still About Safety. A Legislative Fix? .

Data 79

Data Safety Food Pets 79

Healer

MARCH 26, 2021

This article by Hannah Laclaire was originally published by the Portland Press Herald on March 19, 2021. Additional resources on cannabis and opioids: Published data on cannabis treatment to reduce opioid usage. Dr. Sulak’s Cannabis and Opioid Guide. How To Use Cannabis to Reduce & Replace Opioids. Play video.

Chronic Pain 52

Chronic Pain Therapy Data Patients 52

Healer

MARCH 26, 2021

This article by Hannah Laclaire was originally published by the Portland Press Herald on March 19, 2021. Additional resources on cannabis and opioids: Published data on cannabis treatment to reduce opioid usage. Dr. Sulak’s Cannabis and Opioid Guide. How To Use Cannabis to Reduce & Replace Opioids. Play video.

Chronic Pain 52

Chronic Pain Therapy Data Patients 52

Healer

MARCH 26, 2021

This article by Hannah Laclaire was originally published by the Portland Press Herald on March 19, 2021. Additional resources on cannabis and opioids: Published data on cannabis treatment to reduce opioid usage. Dr. Sulak’s Cannabis and Opioid Guide. How To Use Cannabis to Reduce & Replace Opioids. Play video.

Chronic Pain 52

Chronic Pain Therapy Data Patients 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

MARCH 2, 2021

They argued that their findings suggest that doctors “outside of the VHA system who treat veteran patients may need to take the lead in conversations surrounding medical marijuana as a treatment option.”. While medical marijuana is a legal treatment option in 33 states and Washington D.C., Pain management was mentioned by 7.8%

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Eric Rahn, Managing Director.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

SEPTEMBER 28, 2021

The data will then be analysed to recognise trends in responses. • Participants: The survey is open to all ACT residents over 18 years. • Use of Data and Feedback: The data will be used in my ANIP thesis and possibly for future research. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data.

Therapy 52

Therapy Medicine Data Collective 52